Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25033220 | 1.00 | GPR119 (0.33) | GPR119SMN1; SMN2AKR1C3AKR1C2CA12 | |
| SCHEMBL25033222 | 0.83 | LMNA (0.31) | GPR119LMNA | |
| SCHEMBL30832674 | 0.83 | LMNA (0.31) | GPR119LMNA | |
| SCHEMBL23144207 | 0.78 | HRH4 (0.43) | GPR119SMN1; SMN2LMNA | |
| SCHEMBL29811800 | 0.78 | HRH4 (0.43) | GPR119SMN1; SMN2LMNA | |
| SCHEMBL31363594 | 0.77 | GPR119 (0.37) | GPR119SMN1; SMN2AKR1C3AKR1C2CA12 | |
| SCHEMBL23144238 | 0.76 | KCNH2 (0.39) | GPR119SMN1; SMN2 | |
| SCHEMBL29212409 | 0.74 | GPR119 (0.42) | GPR119SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL23155514 | 0.72 | KDM4E (0.39) | GPR119SMN1; SMN2 | |
| SCHEMBL31401161 | 0.69 | PKM (0.40) | SMN1; SMN2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | GPR119 4273/4885SMN1; SMN2 4553/4885AKR1C3 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.